Phase 2 N=72 CT-011 MAb in DLBCL Patients Following ASCT
Lymphoma, Large Cell, Diffuse · Lymphoma, Mixed Cell, Diffuse · Primary Mediastinal Large B-Cell Lymphoma
Primary: Progression-free Survival — 72 Percent
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=45 Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
Myeloma · Lymphoma
Primary: Patients Achieving Greater Than or Equal to 5 x 10^6 of CD34+ Cells/kg in a Single Day of Apheresis — 9; 17 participants
Phase 2 N=26 Exenatide in Extreme Pediatric Obesity
Obesity
Primary: Percent Change From Baseline in Body Mass Index at 3-months — -2.9; -0.15 percentage of change in BMI
Phase 4 N=20 Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
Branch Retinal Vein Occlusion
Primary: Change in ETDRS Best Corrected Visual Acuity From Baseline at 54 Weeks — 14 ETDRS letters
N/A N=239 A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs)
Schizophrenia · Psychotic Disorders
Primary: Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: Body…
Phase 3 N=141 Treating Violence-Prone Substance Use Disorder Patients
Substance-related Disorders · Violence
Primary: Addiction Severity Index Legal Composite — .038; .012 units on a scale
Phase 2 N=141 The Fibrin Patch Soft Tissue Study
Hemostasis
Primary: Proportion of Subjects Achieving Hemostatic Success — 98.3; 53.3; 98.0 percentage of success
N/A N=27 Muscle Weakness and Post-traumatic Knee OA
Meniscectomy
Primary: Change in International Knee Documentation Committee (IKDC) Subjective Knee Form Score — 22.2; 20.6 units on a scale
Phase 3 N=365 Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
Mild Cognitive Impairment · Alzheimer's Disease
Primary: Hazard Ratio (HR) by PET Scan Readers for Conversion to Probable Alzheimer's Disease Based on Visual Image Interpretation. — 3.418; 1.962; 2.561; 2.633 Ratio of visual…
N/A N=33 Erwinase Study in Patients With Acute Lymphoblastic Leukemia
Leukemia
Primary: Participant Toxicity Data
N/A N=43 Metabolic Parameters 3 Months, 9 Months, and 2 Years After Bariatric Surgery
Obesity · Diabetes · Heart Failure
Primary: Change in Weight — -21.5; -16.4 kg — p=<.0001
N/A N=6 Rebreathing of Carbon Dioxide With a Device Used for Giving Inhalational Anaesthesia
Anesthetic Ventilatory Requirements
Primary: Airway Dead Space With Devices for Heat and Moisture Exchange of Respiratory Gas. — 136 mL
N/A N=17 Phenytoin and Multidose Activated Charcoal
Phenytoin Toxicity
Primary: Time of Elimination of Phenytoin in Patients With Elevated Phenytoin Levels — 41.1; 19.3 hours — p=0.049
N/A N=33 Effect of Mirror Therapy on Lower Extremity Motor Control and Gait in Patients With Stroke
Stroke
Primary: Functional Independence Measure - Locomotor Score — 1.65; 1.33; 3.82; 4.25 outcome score
N/A N=290 REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Alzheimer Disease
Primary: Center for Epidemiological Studies-Depression Scale (CES-D) — 4.8; 7.0; 6.4; 5.5 score on a scale